Evaluation of Home Treatment for Acute Psychiatric Care

Mental Disorder Clinical Trial

Official title:

Evaluation of Home Treatment for Acute Psychiatric Care of the Psychiatric University Hospital Zurich (Switzerland)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03320720
• Other study ID #: HT201701349
• Status: Not yet recruiting
• Phase: N/A
• First received: October 19, 2017
• Last updated: October 24, 2017
• Start date: November 2017
• Est. completion date: November 2020

Study information

• Verified date: October 2017
• Source: Psychiatric University Hospital, Zurich
• Contact: Matthias Jäger, MD
• Phone: 0041 44 384 26 37
• Email: matthias.jaeger[@]puk.zh.ch
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study's goal is to evaluate whether home treatment is an effective and efficient alternative to inpatient care for people with acute mental illness. Patients who meet the study's inclusion criteria are randomly assigned to either the condition home treatment or inpatient care (treatment-as-usual), during one year. Following two years, the two treatment modalities will be analyzed in terms of inpatient days, cost effectiveness, rehospitalization rate, severity of symptoms and sociodemographics.

Description:

The study's goal is to evaluate whether home treatment is an effective and efficient alternative to inpatient care for people with acute mental illness. Therefore, psychiatric patients in need of hospitalization who meet the study's inclusion criteria are randomly assigned to either the condition home treatment or inpatient care (treatment-as-usual) during one year. Home treatment patients are visited by a mobile and multiprofessional care team at their homes. Additionally, patients without a health insurance for home treatment and patients who are directly assigned to home treatment are included in separate study groups. Following two years, it will be checked whether home treatment leads to a reduction of inpatient days as a primary outcome. Further outcomes such as cost effectiveness, rehospitalization rate, severity of symptoms and sociodemographics will be also analyzed.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 700
• Est. completion date: November 2020
• Est. primary completion date: November 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Need for acute psychiatric inpatient care

• Residence in Zurich city

• Health insurance for Home Treatment

Exclusion Criteria:

Related Conditions & MeSH terms

• Mental Disorder
• Mental Disorders
• Psychotic Disorders

Intervention

Other:
• Home Treatment
Patients with acute mental illness in need of inpatient care are treated at their houses by a mobile and multiprofessional care team if their health condition permits.
• Treatment-as-usual
Patients with acute mental illness in need of inpatient care are treated in a psychiatric clinic.

Locations

Country	Name	City	State
Switzerland	Psychiatric University Hospital Zurich	Zürich	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
Psychiatric University Hospital, Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Inpatient days	Number of inpatient days per patient	2 years follow-up
Secondary	Total days in treatment	Total days in Treatment per patient = inpatient and home treatment	2 years follow-up
Secondary	Treatment costs	Calculated direct treatment costs	2 years follow-up
Secondary	Rehospitalization rate	Number of rehospitalizations per patient and duration until rehospitalization	2 years follow-up
Secondary	Adverse events	e.g. suicide or attempted suicide	2 years follow-up
Secondary	Global Assessment of Functioning Scale (GAF)	Scale measures social, occupational and psychological functioning and ranges from 0 to 100 (higher values mean better outcome).	2 years follow-up
Secondary	Health of the Nation Outcome Scale (HoNOS)	Scale measures the severity of symptoms and ranges from 0 to 48 (higher values mean worse outcome).	2 years follow-up
Secondary	Clinical Global Impression Scale (CGI)	Scale measures the severity of symptoms, global improvement and therapeutic response and ranges from 0 to 7 (higher values mean worse outcome).	2 years follow-up
Secondary	Patients' satisfaction	Patients' satisfaction assessed by the official questionnaire of the national association of the quality development in hospitals (ANQ)	2 years follow-up